AnGes (4563) AI Stock Analysis

• Market Cap: $21.64B
• Dividend Yield: N/A
• Average Volume (3M): 5.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 179.79%
• EPS Growth: -204.13%
• Country: JP
• Employees: 55
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -3.99
• Shares Outstanding: 338,115,540
• 10 Day Avg. Volume: 5,737,500
• 30 Day Avg. Volume: 5,383,093
• PEG Ratio: <0.01
• Price to Book (P/B): 8.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score reflects significant financial challenges, including negative margins and cash flow issues. While technical indicators show some positive momentum, the valuation remains concerning with a negative P/E ratio. The stock's performance is heavily influenced by its financial state, posing substantial risks without strategic improvements.

AnGes Business Overview & Revenue Model

Company Description

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

How the Company Makes Money

AnGes makes money through the development and commercialization of its proprietary gene-based medicines and therapies. Revenue streams primarily include product sales, licensing agreements, and collaborative partnerships with other pharmaceutical and biotechnology companies. The company often enters into strategic alliances to co-develop and market its products, which helps in cost-sharing and expanding market reach. Additionally, AnGes may receive milestone payments and royalties based on the commercial success of its licensed products. Funding from governmental and non-governmental grants also contributes to its financial resources, supporting ongoing research and development activities.

AnGes Financial Statement Overview

Summary

AnGes faces significant financial hurdles, with deeply negative income margins and cash flow challenges. The low-debt profile is positive, but the inability to generate positive cash flow and profitability raises concerns about operational efficiency and strategic direction.

Income Statement

AnGes has faced significant challenges in maintaining profitability. The company's EBIT and Net Income margins are deeply negative, indicating considerable losses. While revenue has grown from previous periods, the growth is overshadowed by substantial operating losses. This points to potential structural or strategic challenges in its operations.

Balance Sheet

The balance sheet reflects a moderate financial structure with some areas of concern. The debt-to-equity ratio is low, which is a positive sign of limited leverage. However, the consistent decline in stockholders' equity over recent years and negative net income impact return on equity. Despite a negative net debt position, indicating more cash than debt, persistent losses raise concerns about long-term sustainability.

Cash Flow

Cash flow analysis reveals ongoing cash constraints, with persistent negative free cash flow. The operating cash flow is also negative, further emphasizing cash management challenges. The company has relied on financing activities to support cash flow needs, indicating a dependency on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
643.00M	152.99M	67.06M	64.15M	40.00M
	Gross Profit
247.00M	18.98M	-2.92B	7.43M	16.98M
	EBIT
-9.11B	-11.97B	-16.32B	-15.63B	-5.60B
	EBITDA
-5.74B	-8.86B	-13.41B	-13.21B	-4.19B
	Net Income Common Stockholders
-28.13B	-7.44B	-14.71B	-13.68B	-4.21B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.71B	4.16B	11.04B	17.90B	11.54B
	Total Assets
4.67B	28.89B	38.82B	45.46B	38.35B
	Total Debt
272.45M	362.68M	1.16B	0.00	0.00
	Net Debt
-1.44B	-3.80B	-9.88B	-17.90B	-11.54B
	Total Liabilities
2.51B	2.79B	8.40B	6.82B	5.67B
	Stockholders Equity
2.16B	26.10B	30.43B	38.63B	32.68B
Cash Flow		Free Cash Flow
-6.69B	-8.84B	-11.23B	-11.46B	-3.04B
	Operating Cash Flow
-6.61B	-8.74B	-11.21B	-11.38B	-2.96B
	Investing Cash Flow
-130.80M	-356.65M	-97.14M	-154.87M	-6.96B
	Financing Cash Flow
4.20B	2.04B	3.57B	17.38B	11.40B

AnGes Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 64.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Neutral. The current price of 64 is below the 20-day moving average (MA) of 68.45, below the 50-day MA of 66.30, and above the 200-day MA of 58.22, indicating a neutral trend. The MACD of 0.81 indicates Positive momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 6.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4563.

AnGes Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4516	80 Outperform	¥221.19B	6.79		3.77%	6.71%	25.91%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
4563	43 Neutral	$21.64B	―	-193.61%	―	179.79%	-204.13%